KPC Pharmaceuticals,Inc.

600422

CNE0000015P8

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 15/07/2024 am IST			5-day change	1st Jan Change
16.99 ^CNY	-0.18%		-1.96%	-18.55%

08/06	KPC Pharmaceuticals,Inc agreed to acquire 51% stake in China Resources Kunming Shenghuo Pharmaceutical Co., Ltd. from China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. for CNY 1.8 billion.	CI
19/04	KPC Pharmaceuticals,Inc Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

KPC Pharmaceuticals, Inc. Announces Executive Changes

March 02, 2016

KPC Pharmaceuticals, Inc. announced the resignation of Yuan Pingdong from position of Chairman of Directorate and Electing Wang Siyang as New Chairman of Directorate.

Latest news about KPC Pharmaceuticals,Inc.

KPC Pharmaceuticals,Inc agreed to acquire 51% stake in China Resources Kunming Shenghuo Pharmaceutical Co., Ltd. from China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. for CNY 1.8 billion.	08/06	CI
KPC Pharmaceuticals,Inc Reports Earnings Results for the First Quarter Ended March 31, 2024	19/04	CI
Kunyao Group Receives Clinical Trial Approval for FMF Drug	17/04	MT
KPC Pharmaceuticals,Inc Proposes Cash Dividend	22/03	CI
KPC Pharmaceuticals,Inc Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
KPC Pharmaceuticals,Inc Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
KPC Pharmaceuticals’ Antimalarial Drug Passes WHO Prequalification	13/23/13	MT
KPC Pharmaceuticals' Attributable Profit Rises 3.1%; Shares Slip 4%	30/23/30	MT
KPC Pharmaceuticals,Inc Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
KPC Pharmaceuticals' Q1 Net Profit Jumps; Shares Rise 7%	28/23/28	MT
KPC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
KPC Pharma’s Shingles Drug Added to China’s Medical Insurance Catalog	20/23/20	MT
KPC Pharma to Hold Phase II Clinical Trial of Stroke Drug	20/23/20	MT
China Resources Pharmaceutical Completes Transfer of KPC Pharmaceutical Shares to Unit	03/23/03	MT
KPC Pharmaceuticals CFO Steps Down	02/23/02	MT
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. completed the acquisition of a 28% stake in KPC Pharmaceuticals, Inc. from Hofon Pharmaceuticals Co.,Ltd. and Holley Group Company Limited.	30/22/30	CI
KPC Pharmaceuticals, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	24/22/24	CI
KPC Pharmaceuticals Unit Receives Marketing Authorization of Angong Niuhuang Pills; Shares Jump 7%	21/22/21	MT
KPC Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	15/22/15	CI
Chinese Shares Rebound; KPC Pharma Rallies 10% on CR Sanjiu’s $431 Million Stake Purchase	10/22/10	MT
CR Sanjiu Medical & Pharma to Buy 28% Stake in KPC Pharma For $430 Million	10/22/10	MT
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. agreed to acquire 28% stake in KPC Pharmaceuticals, Inc. from Hofon Pharmaceuticals Co.,Ltd. and Holley Group Company Limited for CNY 2.9 billion.	08/22/08	CI
KPC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	15/22/15	CI
KPC Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	18/22/18	CI
KPC Pharmaceuticals, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021	21/21/21	CI

Chart KPC Pharmaceuticals,Inc.

Duration

Period

More charts

KPC Pharmaceuticals, Inc. is a China-based company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company's main products include natural herbal medicines, traditional Chinese medicines and chemical synthetic drugs, such as central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines and anti-inflammatory drugs, among others. The Company is also engaged in the production of health products and provision of medical services.

Sector

Pharmaceuticals

Calendar

23/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for KPC Pharmaceuticals,Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.99 CNY

Average target price

25.01 CNY

Spread / Average Target

+47.20%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KPC PHARMACEUTICALS,INC.	-18.55%	177.31Cr
ELI LILLY AND COMPANY	+63.05%	86TCr
NOVO NORDISK A/S	+39.02%	63TCr
JOHNSON & JOHNSON	-4.78%	36TCr
MERCK & CO., INC.	+17.52%	32TCr
ABBVIE INC.	+8.43%	30TCr
ASTRAZENECA PLC	+13.68%	24TCr
ROCHE HOLDING AG	+4.99%	23TCr
NOVARTIS AG	+16.22%	23TCr
AMGEN INC.	+14.63%	18TCr

Other Pharmaceuticals